GlassScriptPhysician profile
Sanket Vyas
NPI 1932263613
$4,775.91
in general payments reported to CMS, 2019-2025
14 companies · $951 in 2025
The $951 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $194 · 2021: $348 · 2022: $407 · 2023: $656 · 2024: $1,229 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.43 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,239.42 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $405.17 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $344.86 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $306.42 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $286.44 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Janssen Pharmaceuticals, INC | $199.34 | 2019-2024 | Spravato |
| Indivior INC. | $193.26 | 2023-2024 | Perseris |
| Tempus Ai, INC | $163.48 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Axsome Therapeutics, INC. | $124.87 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $117.02 | 2019-2025 | Ingrezza |
| Bioxcel Therapeutics, INC. | $89.48 | 2023-2024 | Igalmi |
| Abbvie INC. | $68.73 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.42 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanket Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.